Research Article

Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-α Transgenic Mice

Figure 1

Tacrolimus and its combined treatment with etanercept attenuate the progression of arthritis in hTNF-Tg mice. Etanercept (ETN; 4 mg/kg) was administered subcutaneously twice a week for 4 weeks, and tacrolimus (TAC; 3 mg/kg) was administered orally once daily for 4 weeks. (a) Results are shown as the arthritis score and the (SEM) of five animals per group. (b) Arthritis-associated radiographic changes were evaluated in a blinded manner at the end of the treatment period. The joint destruction score and the of five animals per group are shown. Data are representative of two independent experiments. compared with the vehicle-treated mice (Dunnet’s multiple comparison test).
(a)
(b)